The results of this employee survey demonstrate that beyond migraine severity and medication therapy, there are potentially modifiable employee and provider factors, which significantly reduce lost productivity associated with migraines. OBJECTIVES: Determine prevalence of employees (via selfreport) experiencing migraine (MID) and non-migraine (NMIG) headaches; and extent of reduced productivity (absenteeism and presenteeism) in MIG and NMIG groups. METHODS: A total of 712 Health Risk Assessments were distributed to health care workers in a large, multispecialty medical group in Southern California; 455 returned (64% response rate). Respondents were 87% female; mean age of 45. Responders classified into no headache, migraine (defined by severity and frequency of symptoms using IHS criteria), and non-migraine. Headache sufferers were asked about absenteeism (full and partial days missed due to headache) and presenteeism (days worked with headache and self-reported productivity with headache) over the most recent 4 week period. RESULTS: Twenty-five percent reported having no headaches in past 6 months, 35% had non-migraine headaches, and 40% had migraines. Combining absenteeism and presenteeism, 68.3% MIG and 44.7% NMIG sufferers reported productivity loss due to headaches in the prior 4 week period. MIG sufferers reported a mean of 9.72 hours of lost productivity, of which 8.13 hours were due to presenteeism. NMIG employees reported a mean of 3.94 hours of lost productivity, of which 3.37 were due to presenteeism. On annualized basis, employees with migraines lost total of 15.85 days: 13.21 days due to presenteeism, 1.78 days due to full missed work days and 0.86 days due to partial missed days. The annual cost to the medical group for lost productivity for headache employees is $887,976 ($1247 per employee): $645,161 for MIG sufferers and $229,815 for NMIG employees. CONCLUSIONS: The results of this employee survey demonstrate that migraine headaches are both a prevalent and expensive condition for an employer. The magnitude of the cost is surprisingly large in a health care organization with employees who would be assumed to be fairly sophisticated and have ready access to physicians for diagnosis and treatment.
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COST-EFFECTIVENESS ANALYSIS OF RIZATRIPTAN AND SUMATRIPTAN VERSUS CAFERGOT IN THE ACUTE TREATMENT OF MIGRAINE
Zhang L 1 , Hay JW 2 1 University of Southern California, Los Angeles, CA, USA; 2 USC School of Pharmacy, Los Angeles, CA, USA Both ergotamine and tritpans are currently used in the treatment of acute migraine. Ergotamine is a traditional therapy with lower drug acquisition cost and less headache recurrence. It has been showed that tritpans are more efficacious than ergotamine. But their high acquisition costs and the short duration of action remain as their major disadvantages. OBJECTIVE: The purpose of this study is to provide a comparison of cost-effectiveness of rizatriptan and sumatritpan with Cafergot in the treatment of acute migraine attack. METHODS: Three separate models were developed based on a decision tree (Model 1: rizatriptan vs. Cafergot; Model 2: sumatritpan vs. Cafergot; Model 3: rizatritpan vs. sumatritpan). Time horizon was one year. Costeffectiveness analysis was conducted from the societal perspective using data from the literature. All costs were converted to year 2003 dollars. The CE ratio was expressed in incremental cost/incremental QALYs. RESULTS: Base case evaluation showed that both rizatriptan and sumatriptan dominated Cafergot (provide the cost differences and QALY differences for the different Meds). Sensitivity analysis showed that the CE ratios were sensitive to moderate changes in effectiveness of triptans. The study further showed that rizatritpan is more costeffective than sumatriptan, as evidenced by the negative CE ratio. Cost-effective ratios are not sensitive to changes of key variables, which include efficacy, utility, drug costs, hospitalization cost and patient preference over alternative therapies. CONCLU-SION: Rizatriptan and sumatritpan are both more cost-effective than Cafergot in the treatment of acute migraine attack. Rizatritpan also dominated sumatritpan. Additional quality of life studies are needed to confirm the benefit from using triptans in management of migraine.
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COMPARISON OF CLINICAL EFFICACY AND COST-EFFECTIVENESS BETWEEN ELETRIPTAN 40 MG AND SUMATRIPTAN 100 MG IN THE ACUTE TREATMENT OF MIGRAINE
Healey PJ, Dugar A, Weis K Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY, USA OBJECTIVES: The objectives of this study were to compare the clinical efficacy and cost-effectiveness of eletriptan 40 mg vs. sumatriptan 100 mg for the acute treatment of migraine attack. METHODS: Data were extracted and pooled from three randomized head-to-head clinical trials comparing the efficacy of eletriptan 40 mg and sumatriptan 100 mg. Three composite measures of treatment success were used based on sustained response (no recurrence of moderate to severe headache or use of rescue medication from the stated time period to 24 hours post-dose): 1-hour sustained response, with improvement of headache pain from moderate to severe at baseline to mild or absent within 1 hour; 2-hour sustained response, with improvement to absent or mild pain within 2 hours post-dose; and 2-hour sustained painfree, with improvement to pain-free within 2 hours. The cost per successfully treated patient (CPSTP) was calculated for each outcome based on the wholesale acquisition cost (WAC) for each medication (AnalySource®, September 2003) . The 95% confidence interval (CI) was calculated using bootstrapping technique. RESULTS: Eletriptan 40 mg was superior to sumatriptan 100 mg across each of the three outcomes: 1-hour sustained, 20% vs. 15% (P < 0.01); 2-hour sustained, 41% vs. 34% (P < 0.001); and 2-hour sustained pain-free, 22% vs. 15% (P < 0.0001). The CPSTP was lower for eletriptan than sumatriptan for all three measures: 1-hour sustained response, $81 vs. $129; 2-hour sustained, $40 vs. $57; 2-hour sustained painfree, $74 vs. $133. CONCLUSIONS: Eletriptan 40 mg had consistently greater positive clinical impact than sumatriptan 100 mg in the acute treatment of migraine. The greater efficacy and lower recurrence rate also translated into better cost-effectiveness.
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